Protalix BioTherapeutics, Inc.
PLXNYSEHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M |
| Operating income | −$5.5M | $3.9M | $10.5M | −$13.0M | −$20.5M | $2.7M |
| Net income | −$6.6M | $2.9M | $8.3M | −$14.9M | −$27.6M | −$6.5M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M | $67.9M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M | $95.0M |
| Equity | $48.2M | $43.2M | $33.6M | −$10.6M | −$6.0M | −$27.0M |
| EPS (diluted) | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 | $-0.22 |
| Shares out. | 78.0M | 73.1M | 57.4M | 46.3M | 45.4M | 14.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −10.4%
- Net margin
- −12.5%
- Return on equity
- −13.7%
- Return on assets
- −8.0%
- Return on capital (ROCE)
- −9.9%
- Liabilities / assets
- 41.4%
- Debt / equity
- 0.71×
- Book value / share
- $0.62
- Revenue growth (YoY)
- −1.2%
- Net income growth (YoY)
- −325.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -11.01distress
- Accruals / assets
- 6.5%moderate
- Beneish M-Score
- -0.17elevated
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2007
- NT 10-Qmissed a reporting deadline ↗May 16, 2001
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2001
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2000
- NT 10-Kmissed a reporting deadline ↗Mar 31, 1999
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bashan DrorOfficer — PRESIDENT AND CEO | Dec 19, 2025 | Buy | 56,000 | $1.81 |
| Bar-Shalev AmosDirector | Nov 18, 2025 | Sell | 168 | $1.87 |
| Forster EliotDirector | Sep 3, 2025 | Grant | 7,500 | — |
| Melincoff Gwen ADirector | Sep 3, 2025 | Grant | 7,500 | — |
| Boudes Pol FDirector | Sep 3, 2025 | Grant | 7,500 | — |
| Elze ChristianDirector | Sep 3, 2025 | Grant | 7,500 | — |
| Schwartz AharonDirector | Sep 3, 2025 | Grant | 7,500 | — |
| Ben Zvi ShmuelDirector | Sep 3, 2025 | Grant | 7,500 | — |
| Bar-Shalev AmosDirector | Sep 3, 2025 | Grant | 7,500 | — |
| Naos YaronOfficer — Sr. VP, Operations | Sep 3, 2025 | Grant | 25,000 | — |
| Bashan DrorOfficer — PRESIDENT AND CEO | Sep 3, 2025 | Grant | 195,000 | — |
| Schwartz AharonDirector | Jun 10, 2025 | Buy | 129,000 | $1.60 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.2M | 3.9 | -17.2% |
| Apr 30, 2026 | 5.1M | 9.7 | +7.0% |
| Apr 15, 2026 | 4.7M | 6.7 | +0.5% |
| Mar 31, 2026 | 4.7M | 3.9 | +7.4% |
| Mar 13, 2026 | 4.4M | 4.5 | +4.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 21, 2026
- Results of operationsMay 13, 2026
- Results of operationsMar 18, 2026
- Other material eventMar 9, 2026
- Regulation FD disclosureFeb 11, 2026
- Other material eventJan 30, 2026
- Regulation FD disclosureJan 5, 2026
- Results of operationsNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 21, 2026
- 10-QMay 13, 2026
- 8-KMay 13, 2026
- ARSApr 30, 2026
- DEF 14AApr 30, 2026
- 3/AApr 27, 2026
- SCHEDULE 13G/AMar 30, 2026
- 10-KMar 18, 2026
- 8-KMar 18, 2026
- 8-KMar 9, 2026
- SCHEDULE 13GMar 4, 2026
- 8-KFeb 11, 2026
- 8-KFORM 8-KJan 30, 2026
- 8-KJan 5, 2026
- 4Dec 23, 2025